Minulet

Quick links to important sections

Minulet

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Minulet

Quick Facts

Property Description
Active ingredient Ethinylestradiol, Gestodene
Form Coated tablet (combination pack)
Pharmacological class Combined Hormonal Contraceptive (CHC)
Common use Prevention of pregnancy
Origin Synthetic hormonal derivative

What is Minulet?

Minulet: Definition and Pharmacological Classification

Minulet is defined as a combined hormonal contraceptive (CHC) medicine, exclusively designated for oral administration and classified as a prescription-only medicine. Pharmacologically, it belongs to the third-generation oral contraceptive category, a distinction rooted in its specific synthetic progestogen component, gestodene. The combination approach used in Minulet is clinically recognized for providing effective fertility management. The preparation is consistently presented as coated tablets supplied in a blister pack structured for systematic, cyclic use.

Core Composition and Origin of Minulet

This combination product is composed of two active ingredients: the synthetic estrogen, ethinylestradiol, and the synthetic progestogen, gestodene. Both compounds are entirely synthetic derivatives, ensuring their precise hormonal properties. This dual-hormone structure, utilizing both an estrogen and a progestogen, is supported by pharmacological studies regarding its use as a method for preventing conception. This product targets hormonal management in women of reproductive age.

What is the General Purpose of Minulet?

The primary general therapeutic purpose of Minulet is to provide effective hormonal oral contraception and the prevention of pregnancy. The use of this reversible contraceptive method is a standard clinical recommendation when an individual seeks dependable, non-permanent control over their fertility. Its established efficacy makes it a key component in reproductive planning strategies.

Regulatory References

  1. Minulet Summary of Product Characteristics (SmPC) - HPRA
  2. EMA Combined hormonal contraceptives overview
  3. Oral Contraceptive Pills - StatPearls - NCBI Bookshelf

What side effects are possible with Minulet?

Official Safety Profile Overview

The safety profile of Minulet is formally documented by regulatory authorities, classifying possible effects by frequency and the body's physiological systems. The highest concern is the serious risk of Venous and Arterial Thromboembolism (VTE/ATE), or blood clots, which include deep vein thrombosis, pulmonary embolism, stroke, and heart attack. This risk is typically highest during the first year of initial use or when restarting the medicine after a break of four weeks or more.

Adverse Reactions and Frequencies

Classification Examples of Officially Listed Adverse Reactions
Common (may affect up to 1 in 10 people) Headache, changes to mood or libido, breast tenderness, abdominal pain, nausea, and weight changes.
Uncommon (may affect up to 1 in 100 people) Vomiting, fluid retention, a rise in blood pressure, and migraines.
Serious Adverse Reactions VTE/ATE (blood clots), severe hypertension, certain liver tumours (benign or, very rarely, malignant), and jaundice.

Common adverse reactions relating to the reproductive system include changes to bleeding patterns such as breakthrough bleeding and spotting, which are most frequently observed during the first three months of treatment. Other documented effects are categorized under System-Organ Classes such as Gastrointestinal Disorders, Nervous System Disorders, and Skin and Subcutaneous Tissue Disorders.

Safety Constraints and Considerations

The label defines specific constraints due to increased risk of serious adverse reactions. Use is restricted in individuals with a history of or current VTE/ATE, certain severe liver diseases, or migraine with focal neurological symptoms. Furthermore, the risk of serious cardiovascular events is explicitly documented as being significantly increased by cigarette smoking, particularly in women over 35 years of age.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Minulet overdosage, consistent with information for combined hormonal contraceptives, defines the specific clinical manifestations and mandated emergency actions.

Documented Clinical Presentation

Acute overdosage primarily presents with expected, transient gastrointestinal disturbances, prominently including nausea and vomiting. In the female population, a common potential manifestation following overdosage is withdrawal bleeding, also known as breakthrough bleeding. Regulatory documents specify that overdosage scenarios include instances of accidental ingestion by children.

Severity and Management Requirements

Based on regulatory assessment, acute Minulet overdosage is not likely to be life-threatening, and clinical reports indicate that no severe effects are apparent. The officially described treatment protocol is symptomatic and supportive, designed to manage the transient effects. Management requires continuous monitoring of vital signs (such as heart rate and blood pressure) to assess stability and may involve the administration of activated charcoal in certain extreme circumstances, according to established medical protocols.

Mandated Emergency Action

Despite the generally low acute toxicity classification, regulatory guidance unequivocally requires that individuals seek medical help right away if an overdose is suspected or confirmed. The established official procedure is to contact a poison control center immediately to receive specific, appropriate guidance for determining the necessary supportive care.

Therapeutic Uses of Minulet

What Minulet Treats: Main Uses and Benefits

The use of Minulet focuses on three key therapeutic domains, providing patients with dependable control and symptomatic relief based on its hormonal composition. The primary indication is the prevention of pregnancy.

Dependable Contraception and Symptom Support

Minulet is primarily and consistently used to provide effective, reversible hormonal oral contraception, serving as a reliable foundation for family planning strategies. Beyond contraception, the combined pill may be part of symptomatic management for common cycle-related disorders. It helps address symptom clusters that may become intense or disruptive, is commonly used to help with conditions characterized by periods of severe menstrual cramps (dysmenorrhea), excessive menstrual blood loss (menorrhagia), and persistent acne vulgaris.


“The medication supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.”


By assisting with cycle regularity, this application supports improved day-to-day comfort and helps ease the disruption caused by these intense manifestations. The medication is also considered relevant for the symptomatic management of certain visible conditions linked to systemic hormonal activity, providing supportive relief when symptoms interfere with routine activities.

Quick Fact: Primary Therapeutic Benefit
Fertility Control: Is commonly used for effective, reversible pregnancy prevention.
Symptom Relief: Supports the management of painful periods, heavy bleeding, and hormonal acne.

Regulatory References

  1. HPRA product information

Eligibility and Restrictions for Use

Who Can and Cannot Use Minulet?

This section defines the official eligibility criteria for Minulet (gestodene/ethinylestradiol), based strictly on regulatory prescribing information for patient safety.

Approved and Restricted Populations

Minulet is formally indicated for use by women of reproductive age for the prevention of pregnancy. Efficacy and safety have been established in this adult population.

Population Category Eligibility Status (Regulatory Basis)
Postmenopausal Women Not indicated for use
Pediatric Population Paediatric data are not available
Postpartum Use should begin no sooner than day 28 postpartum due to heightened risk

Absolute Contraindications (Must Not Use)

Minulet is contraindicated and must not be used by individuals with the following official conditions:

  • Thromboembolic Disorders: Current or history of venous or arterial blood clots (VTE/ATE) or known predisposition (e.g., Factor V Leiden).
  • Cardiovascular Risks: Severe hypertension, diabetes mellitus with vascular symptoms, or severe dyslipoproteinaemia.
  • Hepatic Issues: Liver tumors (adenomas/carcinomas) or acute/chronic liver disease with abnormal function.
  • Malignancy: Known or suspected estrogen-dependent cancers (e.g., carcinoma of the breast).
  • Pregnancy: Known or suspected pregnancy. The product is also generally not recommended for women who are actively breastfeeding.
  • Other: History of migraine with focal neurological symptoms, pancreatitis associated with severe hypertriglyceridaemia, or concurrent use with specific antiviral Hepatitis C treatments.

What should I know about interactions with other medicines?

Minulet (ethinylestradiol and gestodene) can interact with various other medications, potentially affecting its contraceptive effectiveness or increasing the concentration of either drug in the body. It is essential to inform your healthcare provider about all prescription drugs, over-the-counter medicines, and herbal supplements you are taking.

Medicines that may Reduce Contraceptive Efficacy

Certain drugs can speed up the breakdown of Minulet's hormones in the liver, leading to lower levels in the blood and a risk of unplanned pregnancy. In such cases, a non-hormonal barrier method of contraception should be used.

Category Examples of Medicines
Anti-epileptics/Anticonvulsants Phenytoin, Carbamazepine, Phenobarbital
Tuberculosis (TB) Treatments Rifampicin, Rifabutin
HIV/Hepatitis C Some antiretrovirals (e.g., Ritonavir)
Other Bosentan, Griseofulvin, St. John's Wort

⬆️ Medicines that may Increase Minulet Levels

Some medicines may inhibit the breakdown of Minulet, which can increase the risk of side effects such as blood clots, nausea, or breast tenderness. These include certain antifungal agents (e.g., Fluconazole, Itraconazole), grapefruit juice, Paracetamol, and high doses of Vitamin C.

️ Other Important Interactions

  • Hepatitis C Virus (HCV) Medicines: Minulet is strictly contraindicated with certain combination regimens for HCV treatment (e.g., those containing Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir, or Glecaprevir/Pibrentasvir) due to the risk of liver enzyme increases. The contraceptive may be restarted following two weeks after completion of this therapy.
  • Lamotrigine: Minulet may decrease the effectiveness of this anti-epileptic medicine, leading to a loss of seizure control. Dosage adjustment may be necessary.

Always consult your doctor before starting or stopping any medication while using Minulet.

Mechanism of Action

Minulet is a combined hormonal preparation containing gestodene, a synthetic progestogen, and ethinylestradiol, a synthetic estrogen. Both compounds function as agonists, binding selectively to their respective progesterone receptors (PR) and estrogen receptors (ER).

The primary mechanism involves the modulation of the hypothalamic-pituitary-ovarian (HPO) axis. The presence of the synthetic steroids suppresses the release of gonadotropin-releasing hormone (GnRH) from the hypothalamus, which, in turn, reduces the pituitary secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). This suppression prevents the follicular maturation necessary for the LH surge, thereby inhibiting the cascade that leads to ovulation.

Secondary mechanistic actions are mediated by gestodene. It alters the cervical mucus consistency, increasing its viscosity to impair sperm motility and transit through the cervix. Additionally, the hormonal profile induces alterations in the endometrium, rendering the uterine lining less receptive to a blastocyst.

Dosage and Administration Information

How to Use Minulet: Official Dosing and Administration

Minulet is administered following a fixed, cyclic schedule as an oral combined hormonal contraceptive, according to the designated regimen. The instructions define the correct route, dose, and timing required for standardized use. This section details the official usage protocol, excluding any safety, efficacy, or therapeutic mechanism information.


Administration and Dosage Protocol

The official route of administration for Minulet is oral, delivered as a coated tablet containing 75 mug of gestodene and 30 mug of ethinylestradiol.

Usage Component Official Labeled Instruction
Standard Daily Dose One active coated tablet per day.
Administration Timing Take at the same time each day.
Intake Condition Can be swallowed whole with or without food.
Preparation Tablets must not be crushed or chewed.
Age Group Rule Restricted to women of reproductive age (post-menarche).

Fixed 28-Day Cyclic Regimen

Minulet is used in continuous, repeated 28-day cycles for as long as control is desired. The schedule is a 21/7 regimen, which dictates the pattern of use:

  1. Active Phase (21 Days): Take one active tablet daily, starting typically on the first day of the natural menstrual period, following the directional arrows on the pack.
  2. Hormone-Free Phase (7 Days): Follow the active phase with a 7-day tablet-free interval or placebo tablets.
  3. New Cycle Start: Begin a new pack immediately after the 7-day break, regardless of the cessation of bleeding.

This specific, structured approach ensures adherence to the fixed-dose schedule.

Recent Clinical Evidence

Minulet: Recent Clinical Evidence

The combined oral contraceptive Minulet contains the active ingredients gestodene (a progestogen) and ethinylestradiol (an estrogen). Clinical research primarily focuses on assessing efficacy in preventing pregnancy and evaluating the safety profile across various patient populations.


Efficacy and Contraceptive Reliability

Studies confirm that combined oral contraceptives containing gestodene and ethinylestradiol, when taken correctly, are highly effective methods of contraception. Efficacy is measured by the Pearl Index, which calculates the number of pregnancies per 100 woman-years of exposure. Typical-use failure rates reflect real-world use and include occasional missed doses, while perfect-use rates are derived from strict adherence to the dosing schedule in trials.

Measure Pearl Index (Pregnancies per 100 Woman-Years)
Perfect Use <1
Typical Use 3 to 9

Non-Contraceptive Benefits

Beyond pregnancy prevention, research has evaluated the potential effects of Minulet on several non-contraceptive health indicators. These include observed effects on the menstrual cycle, such as promoting more regular and lighter bleeding, and a potential reduction in menstrual pain (dysmenorrhea). Furthermore, some evidence suggests an association between the use of combined oral contraceptives and a reduction in the incidence of functional ovarian cysts.


Safety and Risk Profile

Ongoing clinical monitoring and epidemiological studies focus on the risk of venous thromboembolism (VTE), a known side effect of all combined hormonal contraceptives. Preparations containing gestodene are classified as third-generation oral contraceptives. Regulatory analyses assess the comparative VTE risk profiles of different generations of hormonal contraceptives.

Key Studies & References

  1. Combined Hormonal Contraception: MedlinePlus Drug Information
  2. Combined oral contraceptives: safety and efficacy in various conditions
  3. National Institute for Health and Care Excellence (NICE) Guideline: Contraception - Combined hormonal contraception

Frequently Asked Questions (FAQ)

Common questions about Minulet (FAQ)


Q: What happens if I forget to take a Minulet tablet?

A: According to the official product information, forgetting a tablet may lead to a reduced protective effect against pregnancy, particularly if the gap between tablets is too long. The recommended course of action depends on how late the tablet is. If it is less than 12 hours late, the general guidance provided in the product information is to take the missed tablet immediately, and protective effectiveness may be maintained under specific conditions outlined in the leaflet.


Q: Does Minulet help regulate menstrual cycles?

A: Official information indicates that taking Minulet may lead to a more regular cycle. It is also commonly reported that period bleeding becomes lighter and shorter while on the pill. These effects occur as the medication provides a controlled level of hormones throughout the cycle.


Q: Can Minulet cause weight changes?

A: Regulatory documents mention that changes in body weight are recognized as a possible side effect associated with taking Minulet. This may include either an increase or decrease in weight. This potential effect is typically listed under the general list of side effects in the official product information.


Q: Is Minulet safe to use long-term?

A: Studies and official information indicate that Minulet is intended for use as a long-term hormonal contraceptive. The regulatory documents do not specify a maximum duration for its use. However, regulatory bodies suggest regular medical monitoring for all individuals using hormonal contraceptives.


Q: How soon after stopping Minulet can I become pregnant?

A: Following the discontinuation of Minulet, the official information indicates that a return to normal menstrual cycles and fertility is expected. The ability to become pregnant may resume during the first cycle after stopping the medication. The timeframe for this return can vary among individuals.


Q: Does Minulet protect against sexually transmitted infections (STIs)?

A: Regulatory documents state that Minulet is a contraceptive pill designed solely to prevent pregnancy. It is officially stated that it does not offer any protection against sexually transmitted infections (STIs), including HIV. Separate barrier methods, such as condoms, are generally required for protection against STIs.


Q: Can Minulet affect my mood?

A: According to the official product information, changes in mood, including depressive symptoms, are listed as possible side effects associated with hormonal contraceptives like Minulet. While these effects are generally uncommon, they are recognized in regulatory documents as a potential adverse reaction.


Q: How does Minulet prevent pregnancy?

A: Official product information explains that Minulet is primarily effective by stopping the release of an egg from the ovaries, which is known as inhibiting ovulation. It also contributes to pregnancy prevention by thickening the cervical mucus and modifying the lining of the womb.

How should Minulet be stored and disposed of?

Storage and Disposal of Minulet

Minulet (gestodene/ethinylestradiol) coated tablets must be stored according to official regulatory requirements to ensure product stability.


Storage Requirements

The medicine must be stored below 25 C (77 F) and must be protected from light and moisture. To maintain integrity, the tablets must be kept in the original blister pack until the time of use. It is a mandatory requirement to store Minulet out of the sight and reach of children.

Disposal Instructions

Unused or expired Minulet must not be disposed of via wastewater or general household waste. Disposal procedures require returning the unused product to a pharmacist or a local waste disposal company for proper, environmentally safe handling. The product should not be used after the expiry date printed on the packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Minulet found in:

A-Z Index: